ELND005 is used in the treatment of neuropsychiatric disorders such as Alzheimer’s and bipolar.
The company plans to initiate a proof of concept, Phase II study in bipolar disorder.
Elan modified its Collaboration Agreement with Transition Therapeutics in December 2010, following which Transition exercised its opt-out right, and is not funding the development or commercialization of ELND005.
Transition also gave up its 30% ownership of ELND005 to Elan.